A US policy shock, a long-running national-security concern about drug supply, finally crystallized into tariffs, is pushing pharmaceutical manufacturing back onto American soil. The result is a domestic capital-expenditure wave estimated at roughly $370–480 billion of announced commitments through 2030. The durable money in this theme does not sit with the drugmakers, for whom reshoring is a cost, but with the “picks and shovels”: the engineering, process-equipment, and consumables suppliers who design, build, and outfit the new plants. Also this week, we sat down again with $FRTU President Yoel Damas to address Geoinvesting subscriber questions about funding capacity, automation, the audit process, and the company’s capital structure. The conversation focused on whether the company can convert growing demand without taking on unfavorable financing.